Resolution of chronic spontaneous urticaria and atopic dermatitis with upadacitinib in a patient with Crohn's disease

Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract that includes both Crohn's disease and ulcerative colitis. IBD not only causes gastrointestinal symptoms but is also associated with extraintestinal manifestations like inflammatory skin diseases. Recently, upadacitinib, a selective Janus kinase 1 inhibitor, was approved for the treatment of both IBD and atopic dermatitis.